Hematology-Oncologyadverse eventsBệnh bạch cầu lympho mạn tính dòng B (Chronic Lymphocytic Leukemia
Long-Term Efficacy and Safety of First-Line Ibrutinib-Venetoclax in Older Patients with Chronic Lymphocytic Leukemia: Insights from the 67-Month GLOW Study
By MedXY|Oct 5, 2026
The GLOW phase III trial demonstrates that fixed-duration ibrutinib-venetoclax provides superior overall survival, progression-free survival, and safety compared to chlorambucil-obinutuzumab in older/comorbid CLL patients, with durable dise